542 related articles for article (PubMed ID: 10569939)
1. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
2. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
[TBL] [Abstract][Full Text] [Related]
3. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.
Lesueur-Ginot L; Demarquay D; Kiss R; Kasprzyk PG; Dassonneville L; Bailly C; Camara J; Lavergne O; Bigg DC
Cancer Res; 1999 Jun; 59(12):2939-43. PubMed ID: 10383158
[TBL] [Abstract][Full Text] [Related]
4. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
Urasaki Y; Takebayashi Y; Pommier Y
Cancer Res; 2000 Dec; 60(23):6577-80. PubMed ID: 11118036
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.
Zhu L; Zhang X; Lei N; Liu W; Miao Z; Zhuang C; Sheng C; Guo W; Dong G; Yao J; Cheng P; Zhang W
Chem Biodivers; 2012 Jun; 9(6):1084-94. PubMed ID: 22700227
[TBL] [Abstract][Full Text] [Related]
6. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
Lavergne O; Lesueur-Ginot L; Pla Rodas F; Kasprzyk PG; Pommier J; Demarquay D; Prévost G; Ulibarri G; Rolland A; Schiano-Liberatore AM; Harnett J; Pons D; Camara J; Bigg DC
J Med Chem; 1998 Dec; 41(27):5410-9. PubMed ID: 9876111
[TBL] [Abstract][Full Text] [Related]
7. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins.
Lavergne O; Demarquay D; Bailly C; Lanco C; Rolland A; Huchet M; Coulomb H; Muller N; Baroggi N; Camara J; Le Breton C; Manginot E; Cazaux JB; Bigg DC
J Med Chem; 2000 Jun; 43(11):2285-9. PubMed ID: 10841808
[TBL] [Abstract][Full Text] [Related]
9. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
[TBL] [Abstract][Full Text] [Related]
10. The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.
Demarquay D; Huchet M; Coulomb H; Lesueur-Ginot L; Lavergne O; Kasprzyk PG; Bailly C; Camara J; Bigg DC
Anticancer Drugs; 2001 Jan; 12(1):9-19. PubMed ID: 11272292
[TBL] [Abstract][Full Text] [Related]
11. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of new homocamptothecin analogs.
Luo Y; Yu S; Tong L; Huang Q; Lu W; Chen Y
Eur J Med Chem; 2012 Aug; 54():281-6. PubMed ID: 22647222
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel homocamptothecins conjugating with dihydropyrimidine derivatives as potent topoisomerase I inhibitors.
Zhu L; Cheng P; Lei N; Yao J; Sheng C; Zhuang C; Guo W; Liu W; Zhang Y; Dong G; Wang S; Miao Z; Zhang W
Arch Pharm (Weinheim); 2011 Nov; 344(11):726-34. PubMed ID: 21956522
[TBL] [Abstract][Full Text] [Related]
14. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs.
Bailly C
Crit Rev Oncol Hematol; 2003 Jan; 45(1):91-108. PubMed ID: 12482574
[TBL] [Abstract][Full Text] [Related]
15. Insilico analysis of homocamptothecin (hCPT) analogues for anti-tumour activity.
Vadwai V; Devaraj S
Int J Bioinform Res Appl; 2009; 5(6):603-15. PubMed ID: 19887335
[TBL] [Abstract][Full Text] [Related]
16. Analysis of human topoisomerase I inhibition and interaction with the cleavage site +1 deoxyguanosine, via in vitro experiments and molecular modeling studies.
Laco GS; Du W; Kohlhagen G; Sayer JM; Jerina DM; Burke TG; Curran DP; Pommier Y
Bioorg Med Chem; 2004 Oct; 12(19):5225-35. PubMed ID: 15351405
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
Tardy C; Facompré M; Laine W; Baldeyrou B; García-Gravalos D; Francesch A; Mateo C; Pastor A; Jiménez JA; Manzanares I; Cuevas C; Bailly C
Bioorg Med Chem; 2004 Apr; 12(7):1697-712. PubMed ID: 15028262
[TBL] [Abstract][Full Text] [Related]
18. Lamellarin D: a novel potent inhibitor of topoisomerase I.
Facompré M; Tardy C; Bal-Mahieu C; Colson P; Perez C; Manzanares I; Cuevas C; Bailly C
Cancer Res; 2003 Nov; 63(21):7392-9. PubMed ID: 14612538
[TBL] [Abstract][Full Text] [Related]
19. Homocamptothecins: E-ring modified CPT analogues.
Lavergne O; Demarquay D; Kasprzyk PG; Bigg DC
Ann N Y Acad Sci; 2000; 922():100-11. PubMed ID: 11193885
[TBL] [Abstract][Full Text] [Related]
20. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Chourpa I; Riou JF; Millot JM; Pommier Y; Manfait M
Biochemistry; 1998 May; 37(20):7284-91. PubMed ID: 9585542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
